Table 2B.
Baseline clinical characteristics in patients who were in the studies that investigated the association between LVH and the prognosis of AF.
| References | Study type | Criteria of LVH | Groups | n | Age (years) | Male (%) | Paroxysmal AF | OAC (%) | CHA2DS2-VASc Score | Follow-Up (years) |
|---|---|---|---|---|---|---|---|---|---|---|
| Im et al. (22) | Retrospective cohort study | - | LVH | 93 | 62.8 ± 11.1 | 256 (60.8) | 100% | 95(22.6) | 1.92 ± 1.4 | 6.1 ± 4.9 |
| NO LVH | 328 | |||||||||
| Verdecchia et al. (5) | Post-hoc analysis of RCT | SV3 + RaVL > 2.4 mV (men)or >2.0 mV (women) | LVH | 2353 | 71.3 ± 9 | 1,413 (60) | 15% | 1,568 (67) | 3.70 ± 1.4 | 2.0 |
| NO LVH | 8019 | 71.1 ± 9 | 5,358 (67) | 16% | 5,701 (71) | 3.36 ± 1.3 | ||||
| Badheka et al. (20) | Post-hoc analysis of RCT | (LVMI) > 95 g/m2 in (women)or >115 g/m2 (men). | LVH | 1373 | 69.0 ± 8.1 | 760 (55.4) | 49.80% | - | - | 3.5 ± 1.3 |
| NO LVH | 732 | 70.1 ± 8.1 | 443 (60.6) | 57.90% | ||||||
| Padfield et al. (18) | Prospective cohort study | - | LVH | 53 | 61.2 ± 14.2 | 289 (38.5) | 100% | 216 (28.6) | 0.22 ± 0.41 | 6.35 |
| NO LVH | 700 | |||||||||
| De With et al. (21) | Prospective cohort study | (LVMI) > 95 g/m2 in (women)or>115 g/m2 (men). | LVH | 50 | 49 ± 9 | 354 (76) | 70% | - | 1 ± 0.5 | 7.2 |
| NO LVH | 418 |
LVH, left ventricular hypertrophy; RCT, randomized controlled trial; LVMI, left ventricular mass index.